Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Predictive prioritization of functional enhancers in human pancreas cells

ABSTRACT: Predictive prioritization of functional enhancers in human pancreas cells

PROVIDER: PRJNA1028575 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26398700_1.fastq.gz	Fastqsanger.gz
	SRR26398700_2.fastq.gz	Fastqsanger.gz
	SRR26398701_1.fastq.gz	Fastqsanger.gz
	SRR26398701_2.fastq.gz	Fastqsanger.gz
	SRR26398702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 132

Similar Datasets

Predictive prioritization of functional enhancers in human pancreas cells [HiChIP]

Project description:Predictive prioritization of functional enhancers in human pancreas cells [HiChIP]

| PRJNA1028582 | ENA

Predictive prioritization of functional enhancers in human pancreas cells [ATAC-Seq]

Project description:Predictive prioritization of functional enhancers in human pancreas cells [ATAC-Seq]

| PRJNA1028579 | ENA

Predictive prioritization of enhancers associated with pancreatic disease risk

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-10-15 | GSE245484 | GEO

Pancreatic progenitor epigenome maps prioritize type 2 diabetes risk genes with roles in development

Project description:Genetic variants associated with type 2 diabetes (T2D) risk affect gene regulation in metabolically relevant tissues, such as pancreatic islets. Here, we investigated contributions of regulatory programs active during pancreatic development to T2D risk. Interrogation of chromatin maps from developmental precursors throughout pancreatic differentiation of human embryonic stem cells (hESCs) identifies enrichment of T2D variants in pancreatic progenitor-specific stretch enhancers that are not active in islets. Genes associated with progenitor-specific stretch enhancers are predicted to regulate developmental processes, most notably tissue morphogenesis. Through gene editing in hESCs, we demonstrate that progenitor-specific enhancers harboring T2D-associated variants regulate cell polarity genes LAMA1 and CRB2. Knockdown of lama1 or crb2 in zebrafish embryos causes a defect in pancreas morphogenesis and impairs islet cell development. Together, our findings reveal that a subset of T2D risk variants specifically affects pancreatic developmental programs, suggesting that dysregulation of developmental processes can predispose to T2D.

2021-01-19 | GSE149148 | GEO

Parkinson's Disease Risk Enhancers in Microglia

Project description:Parkinson's Disease Risk Enhancers in Microglia

| PRJNA1028658 | ENA

A New Approach Methods Strategy for Risk-based Prioritization of PFAS [hepatocytes]

Project description:A New Approach Methods Strategy for Risk-based Prioritization of PFAS [hepatocytes]

| PRJNA1021237 | ENA

A New Approach Methods Strategy for Risk-based Prioritization of PFAS [cardiomyocytes]

Project description:A New Approach Methods Strategy for Risk-based Prioritization of PFAS [cardiomyocytes]

| PRJNA1021238 | ENA

Identification and analysis of pancreatic islet specific enhancers

Project description:We anticipated that the identification of cis-regulatory regions active in pancreatic islets would help increase our understanding of islet biology and the pathology of diabetes. Towards this end we used histone H3 lysine 4 monomethylation-based nucleosome predictions genome-wide, in conjunction with binding data for PDX1, FOXA2, MAFA, and NEUROD1, to identify 3,654 putative enhancers that are H3K4me1-enriched uniquely in islets as compared to 14 other tissue or cell-types. We show that these islet-specific enhancers are associated with genes with significantly higher islet specificity than genes associated with non-specific enhancers. Further, islet-specific enhancers were not enriched for typical active or repressive histone methylations in embryonic stem cells and liver, suggesting they are formed by de novo histone methylation during pancreas development. We also identify a subset of enhancers bivalently marked by both H3K4me1 and H3K27me3 in adult pancreatic islets. Further, we show that islet-specific enhancers triple- or quadruple- bound by PDX1, MAFA, NEUROD1 and/or FOXA2 are associated with genes with particularly high islet-specificity, and that these loci are enriched in regions with functional activity in islet cell types. Finally, we demonstrate that cytokines reduce H3K4me1 enrichment levels at selected triple- or quadruple-bound islet-specific enhancers, suggesting that epigenetic changes may contribute to cytokine-induced b-cell dysfunction. In conjunction with data from Hoffman et al Genome Research 2010, an analysis of histone modifications and transcription factor binding sites to identify enhancer regions

2011-06-30 | E-GEOD-30298 | biostudies-arrayexpress

Proteomic profiling of pancreatic cyst fluid in patients with pancreatic cystic lesions identifies novel biomarkers of pancreatic cancer risk

Project description:Pancreatic Cancer (PC) has the worst 5-year survival rate of any cancer as of 2024, at just 13%. The late-stage diagnosis of these patients limits their treatment options, further compounding the problem. Early detection of PC, therefore, is the primary concern of most PC research, as it has the potential to make a substantial difference to the treatment and survival of these patients. Pancreatic cystic lesions (PCLs) are fluid-filled sacs, on or inside the pancreas, that have the potential to become premalignant. While some PCLs are completely benign, others have been shown to have malignant potential and could therefore play a role in the progression to PC. Using the 2018 European evidence-based guidelines for pancreatic cystic neoplasms, patients were classified as being either at a low- or high-risk of PC development. In this study, we profile the proteome of pancreatic cyst fluid from low-risk (n=15) and high-risk (n=17) patients with PCLs and identify differentially expressed proteins between these two risk classifications. We show that these PCF-based differentially expressed proteins have potential utility as biomarkers of risk stratification in this setting.

2025-01-06 | PXD057299 | Pride

Parkinson's Disease Risk Enhancers in Microglia [RNA-seq]

Project description:Parkinson's Disease Risk Enhancers in Microglia [RNA-seq]

| PRJNA1028661 | ENA